VivoVec™ Generates Potent CAR-T-Cells In Vivo For the Potential Treatment of Autoimmune Diseases & Cancers
Time: 4:00 pm
day: Conference Day One P3
Details:
- Umoja is developing the VivoVec™ platform of therapeutics designed to be administered directly to patients resulting in the generation of CAR-T-cells in vivo to treat autoimmune diseases and cancers
- Modeling in non-human primates has demonstrated the ability of VivoVec™ to generate highly functional B-cell targeting CAR-T-cells in vivo that drive B-cell depletion and immune reset
- Umoja is evaluating multiple VivoVec™ in vivo CAR-T-cell products in the clinic in autoimmune disease and B-cell malignancies
